SCHEMBL1148375

SCHEMBL1148375

CN(C)c1cc2ccccc2c2c1o[pH]oc1ccc3ccccc3c12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCL1 Q07820 1/20 0.35
▸ KMT2A Q03164 2/20 0.34
▸ AHR P35869 4/20 0.34
▸ CYP1A2 P05177 2/20 0.34
▸ ABCG2 Q9UNQ0 2/20 0.34
▸ PAX8 Q06710 2/20 0.34
▸ CYP1A1 P04798 1/20 0.34
▸ FYN P06241 1/20 0.34
▸ MAPK3 P27361 1/20 0.34
▸ KDM4E B2RXH2 5/20 0.33
▸ ALDH1A1 P00352 4/20 0.33
▸ HNF4A P41235 2/20 0.33
▸ HIF1A Q16665 2/20 0.33
▸ HSD17B10 Q99714 2/20 0.33
▸ CYP1B1 Q16678 1/20 0.33
▸ MAPT P10636 4/20 0.32
▸ RAB9A P51151 4/20 0.32
▸ GAA P10253 3/20 0.32
▸ NPC1 O15118 3/20 0.32
▸ CYP3A4 P08684 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20480431 0.82 MCL1 (0.42) MCL1KMT2AAHRCYP1A2FYN
SCHEMBL6316182 0.80 HSD17B10 (0.46) MCL1KMT2AAHRCYP1A2ABCG2
SCHEMBL29463989 0.80 HSD17B10 (0.46) MCL1KMT2AAHRCYP1A2ABCG2
SCHEMBL14382011 0.76 KDM4E (0.34) KMT2AAHRCYP1A2ABCG2PAX8
SCHEMBL28643217 0.74 CYP1A2 (0.37) KMT2ACYP1A2KDM4EALDH1A1HSD17B10
SCHEMBL20567297 0.73 ABCG2 (0.31) KMT2AABCG2KDM4EALDH1A1MAPT
SCHEMBL16212768 0.71 CYP2A6 (0.42) KMT2AAHRCYP1A2ABCG2PAX8
SCHEMBL25672935 0.71 CYP1A2 (0.43) KMT2AAHRCYP1A2ABCG2PAX8
SCHEMBL11954814 0.71 CYP1A2 (0.42) KMT2AAHRCYP1A2FYNKDM4E
SCHEMBL10109864 0.68 HNF4A (0.45) KMT2AAHRCYP1A2ABCG2PAX8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7884223-B2 N-isopropylphenethylamine; N-(2,6-dimethoxybenzyl)1-phenethylamine; (R,R) N-(1-naphth-1-ylethyl)-1-phenethylamine; high activity; easily accessible DSM IP ASSETS B.V. (NL) 2011-02-08 — — US disclosed
EP-1824868-B1 CHIRAL COMPOUND SUITABLE AS A CATALYST FOR ASYMMETRIC TRANSFER HYDROGENATION DSM IP ASSETS BV (NL) 2010-06-02 — — EP disclosed
US-20080269529-A1 Chiral Compound Suitable as a Catalyst for Asymmetric Transfer Hydrogenation PATHEON HOLDINGS I B.V. (NL) 2008-10-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269529-A1 Chiral Compound Suitable as a Catalyst for Asymmetric Transfer Hydrogenation SLC30A6, SLC39A14, SLC30A5 MCL1 2090/4885KMT2A 2438/4885AHR 394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback